Those findings have supported the submission of label extension applications for Ixchiq in the U.S., Europe, and Canada, targeting the vaccine’s use in adolescents.

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Valneva said the updated results from the phase 3 VLA1553-321 trial “strengthen” the pivotal data previously reported for Ixchiq in adolescents, which supported label extension applications for the ...

The company said the updated results from the phase 3 VLA1553-321 trial “strengthen” the pivotal data previously reported for Ixchiq in adolescents, which supported label extension applications for ...

which supported filing for potential label extension to this age group in the U.S. 1, Europe, and Canada 2. Data from this trial are also expected to support licensure of IXCHIQ ® in Brazil ...

Valneva submitted label extension applications to the U.S. Food and Drug Administration FDA , the European Medicines Agency EMA and Health Canada to potentially extend the use of IXCHIQ to ...

Valneva submitted label extension applications to the U.S. Food and Drug Administration (FDA) 5, the European Medicines Agency (EMA) and Health Canada 6 to potentially extend the use of IXCHIQ ...

1 Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - Valneva 2 Valneva Submits Label Extension Applications for its Chikungunya Vaccine ...